Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06283927 · ClinicalTrials.gov registry record
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
A clinical trial of Glioblastoma and Glioblastoma Multiforme, sponsored by Jasper Gerritsen.
- Recruiting
- Registry status
- 464
- Enrollment target
- 8
- Study locations
NCT06283927: Recruiting study of Glioblastoma and Glioblastoma Multiforme, sponsored by Jasper Gerritsen.
NCT06283927 is a study of Glioblastoma and Glioblastoma Multiforme that is actively recruiting participants, run by Jasper Gerritsen. The registered enrollment target is 464 participants, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (334% higher). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06283927, a study of Glioblastoma and Glioblastoma Multiforme, is actively recruiting participants, sponsored by Jasper Gerritsen.
- RECRUITING
- Registry status
- 464 participants
- Enrollment target
- 8
- Study locations
Study Summary
Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molecular patient subgroups remains ill-defined. The aim of this study, therefore, is to compare the effects of resection and best oncological treatment for recurrent glioblastoma as a whole and in clinically important subgroups. This study is an international, multicenter, prospective observational cohort study. Recurrent glioblastoma patients will undergo tumor resection or best oncological treatment at a 1:1 ratio as decided by the tumor board. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks after surgery and 2) overall survival. Secondary endpoints are: 1) progression-free survival (PFS), 2) NIHSS deterioration at 3 months and 6 months after surgery, 3) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study has been approved by the Medical Ethics Committee (METC Zuid-West Holland/Erasmus Medical Center; MEC-2020-0812). The results will be published in peer-reviewed academic journals and disseminated to patient organisations and media.
Primary Outcome
Time from diagnosis to death from any cause
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Lomustine
- RADIATION Re-irradiation
- PROCEDURE Re-resection
- PROCEDURE Experimental therapy
Study Locations (8)
Other
- University Hospital Leuven - Leuven
- University Hospital Heidelberg - Heidelberg
- Technical University Munich - Munich
- Inselspital Universitätsspital Bern - Bern
South Holland
- Erasmus MC - Rotterdam
- Medical Center Haaglanden - The Hague
California
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2028-01-01 |
What NCT06283927 shows while recruiting
NCT06283927 is an observational study that tracks outcomes without assigning an intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (334% higher).
The record links to 8 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT06283927 lists 8 locations in 4 states (Other, South Holland, California).
Frequently Asked Questions
What is clinical trial NCT06283927 about?
NCT06283927 is a clinical study titled "The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)". Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molecu...
What is the current status of trial NCT06283927?
This trial is currently recruiting. The enrollment target is 464 participants. The study started on 2023-01-01. Estimated completion is 2028-01-01.
What conditions does trial NCT06283927 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, Recurrent Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain.
What interventions are being tested in trial NCT06283927?
The interventions under investigation include: Temozolomide (DRUG), Lomustine (DRUG), Re-irradiation (RADIATION), Re-resection (PROCEDURE), Experimental therapy (PROCEDURE).
Who is sponsoring clinical trial NCT06283927?
This trial is sponsored by Jasper Gerritsen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06283927 being conducted?
This trial has 8 study locations across California, Massachusetts, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06283927's enrollment target sits among peer trials
464 11th of 199 higher than 189 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
- NCT07403721 · 464 participants · Phase 1
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI